{"disease":{"id":"psi","name":"psi"},"drugs":{"marketed":[{"drug_id":"humax-cd20","indication_name":"Relapsing multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arzerra","generic_name":"HuMax-CD20","company_name":"Glaxo Grp Ltd","drug_phase":"discontinued","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody","quality_score":null,"revenue":"3198","mechanism":"Arzerra works by binding to the CD20 protein on B cells, marking them for destruction by the immune system."},{"drug_id":"dimethyl-fumarate","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tecfidera","generic_name":"DIMETHYL FUMARATE","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"dimethyl fumarate","quality_score":59,"revenue":"2800","mechanism":"Tecfidera works by activating the hydroxycarboxylic acid receptor 2, which helps to reduce inflammation and modulate the immune system."},{"drug_id":"teriflunomide","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aubagio","generic_name":"TERIFLUNOMIDE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"dihydroorotate dehydrogenase","drug_class":"Pyrimidine Synthesis Inhibitor [EPC]","quality_score":75,"revenue":"1100","mechanism":"Teriflunomide inhibits dihydroorotate dehydrogenase, reducing activated lymphocytes in the CNS."},{"drug_id":"siponimod","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mayzent","generic_name":"SIPONIMOD","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate receptor 1","drug_class":"Sphingosine 1-phosphate Receptor Modulator [EPC]","quality_score":10,"revenue":"1068","mechanism":"Mayzent works by binding to the sphingosine 1-phosphate receptor 1, which helps to reduce inflammation and slow disease progression."},{"drug_id":"ozanimod","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zeposia","generic_name":"OZANIMOD","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate receptor 1","drug_class":"Sphingosine 1-phosphate Receptor Modulator","quality_score":72,"revenue":"800","mechanism":"Zeposia works by binding to the sphingosine 1-phosphate receptor 1, which helps to reduce inflammation and slow disease progression."},{"drug_id":"interferon-beta-1a","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avonex","generic_name":"INTERFERON BETA-1A","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"Interferon beta [EPC]","quality_score":55,"revenue":"800","mechanism":"Avonex works by binding to the interferon alpha/beta receptor, which helps to reduce inflammation and slow disease progression in multiple sclerosis."},{"drug_id":"peginterferon-beta-1a","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Plegridy","generic_name":"PEGINTERFERON BETA-1A","company_name":"Biogen Idec Inc","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"Interferon beta [EPC]","quality_score":10,"revenue":"800","mechanism":"Plegridy works by binding to the interferon alpha/beta receptor, which helps to reduce inflammation and slow disease progression in multiple sclerosis."},{"drug_id":"cladribine","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Leustatin","generic_name":"CLADRIBINE","company_name":"","drug_phase":"marketed","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4A","drug_class":"Purine Antimetabolite [EPC]","quality_score":75,"revenue":"700","mechanism":"Leustatin works by inhibiting the enzyme that breaks down cyclic adenosine monophosphate (cAMP), leading to an accumulation of cAMP and subsequent activation of various cellular pathways."},{"drug_id":"diroximel-fumarate","indication_name":"Relapsing Forms of Multiple Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vumerity","generic_name":"DIROXIMEL FUMARATE","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"","quality_score":71,"revenue":"500","mechanism":"Vumerity works by binding to the hydroxycarboxylic acid receptor 2, which helps to reduce inflammation in the central nervous system."},{"drug_id":"diroximel-fumarate","indication_name":"Relapsing forms of multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vumerity","generic_name":"DIROXIMEL FUMARATE","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"","quality_score":71,"revenue":"500","mechanism":"Vumerity works by binding to the hydroxycarboxylic acid receptor 2, which helps to reduce inflammation in the central nervous system."},{"drug_id":"fusidic-acid","indication_name":"Sepsis due to Pseudomonas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"fusidic-acid","indication_name":"Sepsis of the newborn","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"doxycyclin","indication_name":"Relapsing fever","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxycyclin","company_name":"Bulovka Hospital","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"laquinimod","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nerventra","generic_name":"LAQUINIMOD","company_name":"Teva","drug_phase":"discontinued","molecular_target":"","drug_class":"laquinimod","quality_score":null,"revenue":null,"mechanism":"Nerventra works by modulating the immune system to reduce inflammation in the central nervous system."},{"drug_id":"gentamicin","indication_name":"Sepsis due to Gram negative bacteria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Garamycin","generic_name":"GENTAMICIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 5","drug_class":"Aminoglycoside Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"gentamicin","indication_name":"Sepsis due to Pseudomonas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Garamycin","generic_name":"GENTAMICIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 5","drug_class":"Aminoglycoside Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"gentamicin","indication_name":"Sepsis of the newborn","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Garamycin","generic_name":"GENTAMICIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 5","drug_class":"Aminoglycoside Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"silver","indication_name":"wound sepsis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Silver Sulfadiazine","generic_name":"SILVER","company_name":"King Pharms Llc","drug_phase":"marketed","molecular_target":"","drug_class":"Sulfonamide Antibacterial [EPC]","quality_score":38,"revenue":null,"mechanism":""},{"drug_id":"acotiamide","indication_name":"Nonulcer dyspepsia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Acofide","generic_name":"ACOTIAMIDE","company_name":"Zeria","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"benzylpenicillin","indication_name":"Sepsis of the newborn","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Penicillin G Potassium In Plastic Container","generic_name":"Benzylpenicillin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"nafcillin-sodium","indication_name":"Sepsis due to Staphylococcus aureus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nallpen In Plastic Container","generic_name":"NAFCILLIN SODIUM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"azathioprine","indication_name":"Relapsing multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imuran","generic_name":"AZATHIOPRINE","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Purine Antimetabolite [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"daptomycin","indication_name":"Sepsis caused by methicillin resistant Staphylococcus aureus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cubicin","generic_name":"Daptomycin","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"lipopeptide antibacterial","quality_score":59,"revenue":null,"mechanism":"Daptomycin is an antibacterial drug with lipopeptide structure."},{"drug_id":"daptomycin","indication_name":"Sepsis due to Staphylococcus aureus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cubicin","generic_name":"Daptomycin","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"lipopeptide antibacterial","quality_score":59,"revenue":null,"mechanism":"Daptomycin is an antibacterial drug with lipopeptide structure."},{"drug_id":"tobramycin","indication_name":"Sepsis due to Pseudomonas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tobi","generic_name":"tobramycin","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"tobramycin","indication_name":"Sepsis of the newborn","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tobi","generic_name":"tobramycin","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"vancomycin","indication_name":"Sepsis of the newborn","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vancocin","generic_name":"vancomycin","company_name":"ANI Pharmaceuticals","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor, D-alanyl-D-alanine dipeptidase, UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"nafcillin","indication_name":"Sepsis due to Staphylococcus aureus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nallpen In Plastic Container","generic_name":"NAFCILLIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefotaxime","indication_name":"Sepsis due to Staphylococcus aureus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Claforan","generic_name":"CEFOTAXIME","company_name":"Sterimax","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"cefotaxime","indication_name":"Sepsis of the newborn","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Claforan","generic_name":"CEFOTAXIME","company_name":"Sterimax","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"ampicillin","indication_name":"Sepsis due to Staphylococcus aureus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"AMPICILLIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 4","drug_class":"Penicillin-class Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"amphotericin-b","indication_name":"Relapsing fever","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abelcet","generic_name":"AMPHOTERICIN B","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Lipid-based Polyene Antifungal [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"demeclocycline","indication_name":"Relapsing fever","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Demethylchlortetracycline","generic_name":"DEMECLOCYCLINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor beta","drug_class":"Tetracycline-class Antimicrobial","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"piperacillin","indication_name":"Sepsis due to Gram negative bacteria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pipracil","generic_name":"PIPERACILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"piperacillin","quality_score":10,"revenue":null,"mechanism":"Pipracil works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death."},{"drug_id":"piperacillin","indication_name":"Sepsis due to Pseudomonas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pipracil","generic_name":"PIPERACILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"piperacillin","quality_score":10,"revenue":null,"mechanism":"Pipracil works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death."},{"drug_id":"tobramycin-sulfate","indication_name":"Sepsis due to Pseudomonas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantobra","generic_name":"Tobramycin Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20","drug_class":"tobramycin","quality_score":68,"revenue":null,"mechanism":""},{"drug_id":"tobramycin-sulfate","indication_name":"Sepsis of the newborn","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantobra","generic_name":"Tobramycin Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20","drug_class":"tobramycin","quality_score":68,"revenue":null,"mechanism":""},{"drug_id":"gentamicin-sulfate","indication_name":"Sepsis due to Gram negative bacteria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gentamicin","generic_name":"Gentamicin Sulfate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"gentamicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"gentamicin-sulfate","indication_name":"Sepsis due to Pseudomonas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gentamicin","generic_name":"Gentamicin Sulfate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"gentamicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"gentamicin-sulfate","indication_name":"Sepsis of the newborn","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gentamicin","generic_name":"Gentamicin Sulfate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"gentamicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"mayzent","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mayzent","company_name":"Novartis Pharmaceuticals","drug_phase":"discontinued","molecular_target":"Sphingosine 1-phosphate receptor 2, Sphingosine 1-phosphate receptor 1, Sphingosine 1-phosphate receptor 3","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"famotidine","indication_name":"Dyspepsia Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pepcid","generic_name":"famotidine","company_name":"Generic (originally Yamanouchi/Merck)","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Solute carrier family 22 member 2","drug_class":"Histamine-2 Receptor Antagonist [EPC]","quality_score":56,"revenue":null,"mechanism":"Competitively blocks histamine H2 receptors on gastric parietal cells, reducing basal and stimulated acid secretion."},{"drug_id":"nebcin","indication_name":"Sepsis due to Pseudomonas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nebcin","company_name":"University Hospital, Lille","drug_phase":"discontinued","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"nebcin","indication_name":"Sepsis of the newborn","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nebcin","company_name":"University Hospital, Lille","drug_phase":"discontinued","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"campath","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Campath","company_name":"National Heart, Lung, and Blood Institute (NHLBI)","drug_phase":"marketed","molecular_target":"CAMPATH-1 antigen","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"meclocycline","indication_name":"Relapsing fever","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Meclan","generic_name":"MECLOCYCLINE","company_name":"Johnson And Johnson","drug_phase":"marketed","molecular_target":"","drug_class":"meclocycline","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"interferon-beta-1b","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betaseron","generic_name":"INTERFERON BETA-1B","company_name":"Bayer Healthcare Pharms","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"Interferon beta","quality_score":10,"revenue":null,"mechanism":"Betaseron works by binding to the interferon alpha/beta receptor, which helps to reduce inflammation and slow disease progression in multiple sclerosis."},{"drug_id":"ublituximab-xiiy","indication_name":"Relapsing forms of multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BRIUMVI","generic_name":"UBLITUXIMAB-XIIY","company_name":"TG THERAPEUTICS, INC","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pazufloxacin","indication_name":"Sepsis due to Streptococcus pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PAZUFLOXACIN","company_name":"","drug_phase":"discontinued","molecular_target":"","drug_class":"pazufloxacin","quality_score":0,"revenue":null,"mechanism":"Pazufloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and transcription."},{"drug_id":"mitoxantrone","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novantrone","generic_name":"MITOXANTRONE","company_name":"","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Topoisomerase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division."},{"drug_id":"vumerity","indication_name":"Relapsing forms of multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vumerity","company_name":"University of Nebraska","drug_phase":"marketed","molecular_target":"Nuclear factor erythroid 2-related factor 2, Hydroxycarboxylic acid receptor 2","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"fingolimod","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gilenya","generic_name":"FINGOLIMOD","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate receptor 1","drug_class":"Sphingosine 1-phosphate Receptor Modulator","quality_score":75,"revenue":null,"mechanism":"Gilenya works by binding to and blocking the S1P1 receptor, preventing immune cells from leaving the lymph nodes and reducing inflammation in the central nervous system."},{"drug_id":"aztreonam","indication_name":"Sepsis due to Gram negative bacteria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azactam","generic_name":"AZTREONAM","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Monobactam Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Aztreonam inhibits bacterial cell wall synthesis, acting as a bactericidal agent."},{"drug_id":"aztreonam","indication_name":"Sepsis due to Pseudomonas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azactam","generic_name":"AZTREONAM","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Monobactam Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Aztreonam inhibits bacterial cell wall synthesis, acting as a bactericidal agent."},{"drug_id":"ertapenem","indication_name":"Miscarriage with sepsis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Invanz","generic_name":"ERTAPENEM","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Penem Antibacterial","quality_score":70,"revenue":null,"mechanism":"Invanz works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"ceftolozane","indication_name":"Sepsis caused by Haemophilus influenzae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zerbaxa","generic_name":"CEFTOLOZANE","company_name":"Cubist Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":"Zerbaxa works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"ceftolozane","indication_name":"Sepsis caused by Serratia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zerbaxa","generic_name":"CEFTOLOZANE","company_name":"Cubist Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":"Zerbaxa works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"amikacin","indication_name":"Sepsis due to Gram negative bacteria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arikayce Kit","generic_name":"AMIKACIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial","quality_score":10,"revenue":null,"mechanism":"Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria."},{"drug_id":"amikacin","indication_name":"Sepsis due to Pseudomonas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arikayce Kit","generic_name":"AMIKACIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial","quality_score":10,"revenue":null,"mechanism":"Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria."},{"drug_id":"amikacin","indication_name":"Sepsis of the newborn","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arikayce Kit","generic_name":"AMIKACIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial","quality_score":10,"revenue":null,"mechanism":"Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria."},{"drug_id":"ceftazidime","indication_name":"Sepsis due to Pseudomonas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"ceftazidime","indication_name":"Sepsis due to Staphylococcus aureus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"cefoxitin","indication_name":"Sepsis due to Staphylococcus aureus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"alemtuzumab","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Campath","generic_name":"ALEMTUZUMAB","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"CAMPATH-1 antigen","drug_class":"CD52-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Campath works by binding to a specific protein on the surface of immune cells, marking them for destruction."},{"drug_id":"fty720","indication_name":"Treatment of relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FTY720","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)","drug_class":"Sphingosine-1-phosphate receptor modulator; Immunomodulator","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin","indication_name":"Sepsis due to Gram negative bacteria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TICARCILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin","indication_name":"Sepsis due to Pseudomonas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TICARCILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin","indication_name":"Sepsis due to Staphylococcus aureus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TICARCILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin-disodium","indication_name":"Sepsis due to Gram negative bacteria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ticarcillin","generic_name":"TICARCILLIN DISODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin-disodium","indication_name":"Sepsis due to Pseudomonas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ticarcillin","generic_name":"TICARCILLIN DISODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin-disodium","indication_name":"Sepsis due to Staphylococcus aureus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ticarcillin","generic_name":"TICARCILLIN DISODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"clavulanic-acid","indication_name":"Sepsis due to Pseudomonas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Augmentin 250","generic_name":"CLAVULANIC ACID","company_name":"Dr Reddys Labs Inc","drug_phase":"marketed","molecular_target":"","drug_class":"beta Lactamase Inhibitor","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"clavulanic-acid","indication_name":"Sepsis due to Staphylococcus aureus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Augmentin 250","generic_name":"CLAVULANIC ACID","company_name":"Dr Reddys Labs Inc","drug_phase":"marketed","molecular_target":"","drug_class":"beta Lactamase Inhibitor","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"tazicef","indication_name":"Sepsis due to Pseudomonas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"Ceftazidime","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"Bacterial cell wall","drug_class":"Third-generation cephalosporin","quality_score":10,"revenue":null,"mechanism":"Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance."},{"drug_id":"tazicef","indication_name":"Sepsis due to Staphylococcus aureus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"Ceftazidime","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"Bacterial cell wall","drug_class":"Third-generation cephalosporin","quality_score":10,"revenue":null,"mechanism":"Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance."},{"drug_id":"tazobactam","indication_name":"Sepsis caused by Haemophilus influenzae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zosyn","generic_name":"TAZOBACTAM","company_name":"Merck Sharp & Dohme B.V.","drug_phase":"marketed","molecular_target":"","drug_class":"beta Lactamase Inhibitor","quality_score":50,"revenue":null,"mechanism":"Zosyn works by blocking bacterial enzymes that break down antibiotics, allowing the antibiotics to kill bacteria more effectively."},{"drug_id":"tazobactam","indication_name":"Sepsis caused by Serratia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zosyn","generic_name":"TAZOBACTAM","company_name":"Merck Sharp & Dohme B.V.","drug_phase":"marketed","molecular_target":"","drug_class":"beta Lactamase Inhibitor","quality_score":50,"revenue":null,"mechanism":"Zosyn works by blocking bacterial enzymes that break down antibiotics, allowing the antibiotics to kill bacteria more effectively."},{"drug_id":"norfloxacin","indication_name":"Miscarriage with sepsis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ceftizoxime","indication_name":"Sepsis due to Staphylococcus aureus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epocelin","generic_name":"CEFTIZOXIME","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"olutasidenib","indication_name":"Relapsing acute myeloid leukemia with a susceptible IDH1 mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rezlidhia","generic_name":"OLUTASIDENIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"mutated IDH1","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Olutasidenib inhibits mutated IDH1, reducing 2-HG levels in AML cells."},{"drug_id":"minocycline","indication_name":"Relapsing fever","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Minocycline Hydrochloride","generic_name":"MINOCYCLINE","company_name":"Rempex","drug_phase":"marketed","molecular_target":"","drug_class":"Tetracycline-class Drug","quality_score":75,"revenue":null,"mechanism":"MINOCYCLINE works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"doxycycline","indication_name":"Relapsing fever","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"oxacillin","indication_name":"Sepsis due to Staphylococcus aureus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bactocill In Plastic Container","generic_name":"OXACILLIN","company_name":"Apothecon","drug_phase":"marketed","molecular_target":"Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cubicin","indication_name":"Sepsis caused by methicillin resistant Staphylococcus aureus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cubicin","company_name":"Clinical Alliance for Research & Education - Infectious Diseases, LLC.","drug_phase":"marketed","molecular_target":"Outer membrane porin protein OmpD","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cubicin","indication_name":"Sepsis due to Staphylococcus aureus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cubicin","company_name":"Clinical Alliance for Research & Education - Infectious Diseases, LLC.","drug_phase":"marketed","molecular_target":"Outer membrane porin protein OmpD","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"penicillin","indication_name":"Sepsis of the newborn","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"penicillin","company_name":"Karlstad University","drug_phase":"marketed","molecular_target":"Bacterial penicillin-binding protein, Beta-lactamase, Beta-lactamase TEM","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"avonex","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avonex","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"gilenya","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gilenya","company_name":"University of Southern California","drug_phase":"marketed","molecular_target":"Sphingosine-1-phosphate lyase 1, Sphingosine 1-phosphate receptor 1, Sphingosine 1-phosphate receptor 3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"plegridy","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Plegridy","company_name":"Holy Name Medical Center, Inc.","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"arzerra","indication_name":"Relapsing multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Arzerra","company_name":"GlaxoSmithKline","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ceftazidim","indication_name":"Sepsis due to Pseudomonas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftazidim","company_name":"Tel-Aviv Sourasky Medical Center","drug_phase":"marketed","molecular_target":"Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ceftazidim","indication_name":"Sepsis due to Staphylococcus aureus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftazidim","company_name":"Tel-Aviv Sourasky Medical Center","drug_phase":"marketed","molecular_target":"Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"betaseron","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Betaseron","company_name":"University of Medicine and Dentistry of New Jersey","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dapt","indication_name":"Sepsis caused by methicillin resistant Staphylococcus aureus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DAPT","company_name":"Baxter Hlthcare Corp","drug_phase":"marketed","molecular_target":"Outer membrane porin protein OmpD","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Dapt is a small molecule that works by interacting with specific biological targets, but the exact details of this interaction are unknown."},{"drug_id":"dapt","indication_name":"Sepsis due to Staphylococcus aureus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DAPT","company_name":"Baxter Hlthcare Corp","drug_phase":"marketed","molecular_target":"Outer membrane porin protein OmpD","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Dapt is a small molecule that works by interacting with specific biological targets, but the exact details of this interaction are unknown."},{"drug_id":"tecfidera","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tecfidera","company_name":"EMD Serono Research & Development Institute, Inc.","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2, Kelch-like ECH-associated protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zenapax","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zenapax","company_name":"National Institute of Neurological Disorders and Stroke (NINDS)","drug_phase":"phase_3","molecular_target":"Interleukin-2 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"mitozantrone","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mitozantrone","company_name":"US Department of Veterans Affairs","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, ATP-binding cassette sub-family G member 2, DNA-(apurinic or apyrimidinic site) lyase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"minocyclin","indication_name":"Relapsing fever","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Minocyclin","company_name":"University of Southern California","drug_phase":"marketed","molecular_target":"30S ribosomal protein S4, 30S ribosomal protein S9, Tetracycline resistance protein, class B","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"daclizumab","indication_name":"Relapsing remitting multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zenapax","generic_name":"DACLIZUMAB","company_name":"Hoffman-La Roche","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"Interleukin-2 Receptor Blocking Antibody","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"acetazolamide","indication_name":"Centrencephalic epilepsies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diamox","generic_name":"ACETAZOLAMIDE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Carbonic anhydrase","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"mitoxantrone","indication_name":"Multiple Sclerosis - Progressive Relapsing","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novantrone","generic_name":"MITOXANTRONE","company_name":"","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Topoisomerase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division."},{"drug_id":"mitoxantrone","indication_name":"Multiple Sclerosis - Worsening Relapsing-Remitting","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novantrone","generic_name":"MITOXANTRONE","company_name":"","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Topoisomerase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division."},{"drug_id":"desmopressin","indication_name":"Post-Trauma/Surgery Polyuria and Polydipsia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ddavp","generic_name":"DESMOPRESSIN","company_name":"Ferring Pharms Inc","drug_phase":"marketed","molecular_target":"Vasopressin V1b receptor","drug_class":"Factor VIII Activator","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"fingolimod-hydrochloride","indication_name":"Relapsing Forms of Multiple Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FINGOLIMOD HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"doxycycline","indication_name":"Psittacosis (ornithosis)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"doxycycline","indication_name":"Relapsing fever","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"fusidic-acid","indication_name":"Relapsing fever","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"fusidic-acid","indication_name":"Sepsis due to Gram negative bacteria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."}],"pipeline":[{"drug_id":"chlorthalidone","indication_name":"Cardiac effects of mineralocorticoid receptor antagonism after preeclampsia","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CHLORTHALIDONE","company_name":"","drug_phase":"marketed","molecular_target":"Na+/Cl− cotransporter","drug_class":"Thiazide-like Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":109,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT06619535","title":"Sepsis As a Cause of Death Among Elderly Cancer Patients","phase":"","overall_status":"COMPLETED","enrollment_count":5239194,"lead_sponsor_name":"asmaa salama ibrahim","has_results":false},{"nct_id":"NCT04017221","title":"Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes","phase":"","overall_status":"COMPLETED","enrollment_count":1249636,"lead_sponsor_name":"Canadian Network for Observational Drug Effect Studies, CNODES","has_results":false},{"nct_id":"NCT06148532","title":"EnCoRe MoMS: Engaging Communities to Reduce Morbidity From Maternal Sepsis (Aim 2)","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":400000,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT05810545","title":"Drinking Water PFAS, Pregnancy Outcome and Maternal Morbidity","phase":"","overall_status":"COMPLETED","enrollment_count":256659,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT03489447","title":"Mortality of Sepsis in Swedish Intensive Care Units 2008-2016","phase":"","overall_status":"COMPLETED","enrollment_count":252245,"lead_sponsor_name":"Uppsala University","has_results":false},{"nct_id":"NCT03330301","title":"D-tecting Disease - From Exposure to Vitamin D During Critical Periods of Life","phase":"","overall_status":"COMPLETED","enrollment_count":222776,"lead_sponsor_name":"Bispebjerg Hospital","has_results":false},{"nct_id":"NCT06368336","title":"Health Related Quality of Life After Intensive Care for Sepsis, a National Cohort Study.","phase":"","overall_status":"COMPLETED","enrollment_count":210484,"lead_sponsor_name":"Uppsala University Hospital","has_results":false},{"nct_id":"NCT04148989","title":"Effects of Code Sepsis Implementation on Emergency Department (ED) Sepsis Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":180402,"lead_sponsor_name":"Intermountain Health Care, Inc.","has_results":true},{"nct_id":"NCT06779617","title":"UMMS Sepsis Early Prediction Score (SEPSys) and RESCUE Score Combined Clinical Trial","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":150000,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT02468310","title":"Evaluating the Effects of SMS Text Messaging Support System Among Frontline Health Workers in Ghana","phase":"NA","overall_status":"COMPLETED","enrollment_count":65831,"lead_sponsor_name":"Hannah Brown Amoakoh","has_results":false},{"nct_id":"NCT04078594","title":"Electronic Early Notification of Sepsis in Hospitalized Ward Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":65250,"lead_sponsor_name":"King Abdullah International Medical Research Center","has_results":false},{"nct_id":"NCT04904289","title":"Early Recognition and Dynamic Risk Warning System of Multiple Organ Dysfunction Syndrome Caused by Sepsis","phase":"","overall_status":"UNKNOWN","enrollment_count":60000,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06354452","title":"Effect of Statin Therapy on Sepsis-related Mortality in Intensive Care Unit Patients","phase":"","overall_status":"COMPLETED","enrollment_count":59578,"lead_sponsor_name":"Hospital de Granollers","has_results":false},{"nct_id":"NCT03871491","title":"Azithromycin-Prevention in Labor Use Study (A-PLUS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":58747,"lead_sponsor_name":"NICHD Global Network for Women's and Children's Health","has_results":true},{"nct_id":"NCT07317817","title":"Research on Risk Assessment and Early Warning Models for Adverse Clinical Outcomes in Critically Ill Patients","phase":"","overall_status":"COMPLETED","enrollment_count":55940,"lead_sponsor_name":"Chongqing Medical University","has_results":false},{"nct_id":"NCT05072145","title":"Evaluating Tele-Emergency Care in Costs and Outcomes for Rural Sepsis Patients","phase":"","overall_status":"COMPLETED","enrollment_count":55772,"lead_sponsor_name":"Nicholas M Mohr","has_results":false},{"nct_id":"NCT06845332","title":"Promoting Optimal Treatment Choices in Neonates With Suspected Early-Onset Sepsis","phase":"","overall_status":"RECRUITING","enrollment_count":55000,"lead_sponsor_name":"Franciscus Gasthuis","has_results":false},{"nct_id":"NCT03752489","title":"Unsupervised Machine Learning for Clustering of Septic Patients to Determine Optimal Treatment","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":51645,"lead_sponsor_name":"Dascena","has_results":false},{"nct_id":"NCT06383858","title":"The Project of Gestational Hypertension and Preeclampsia Screening and Prevention Center","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"The Third Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT03941886","title":"Implementation of First-trimester Screening and preventiOn of pREeClAmpSia Trial (FORECAST)","phase":"NA","overall_status":"COMPLETED","enrollment_count":42454,"lead_sponsor_name":"Chiu Yee Liona Poon","has_results":false},{"nct_id":"NCT05304728","title":"Sepsis Clinical Decision Support [CDS] Master Enrollment Study Protocol","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":40000,"lead_sponsor_name":"Beckman Coulter, Inc.","has_results":false},{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT04005001","title":"Machine Learning Sepsis Alert Notification Using Clinical Data","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":37986,"lead_sponsor_name":"Dascena","has_results":false},{"nct_id":"NCT04615065","title":"Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"University Medical Center Groningen","has_results":false},{"nct_id":"NCT05394961","title":"Factors Associated With Decisions to Withhold or Withdraw Intensive Care","phase":"","overall_status":"COMPLETED","enrollment_count":33256,"lead_sponsor_name":"Uppsala University","has_results":false},{"nct_id":"NCT06145724","title":"EnCoRe MoMS: Engaging Communities to Reduce Morbidity From Maternal Sepsis (Aim 1)","phase":"NA","overall_status":"RECRUITING","enrollment_count":33183,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT03655626","title":"Implementation and Evaluations of Sepsis Watch","phase":"NA","overall_status":"COMPLETED","enrollment_count":32003,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT03151070","title":"Scaling Up an Integrated Approach to Improve Delivery Care in North Guatemala With Stepped Wedge Design","phase":"","overall_status":"COMPLETED","enrollment_count":32000,"lead_sponsor_name":"Hospital San Juan de Dios Guatemala","has_results":false},{"nct_id":"NCT07532564","title":"Risk Factors, Costs, and Impacts of ED Boarding","phase":"","overall_status":"COMPLETED","enrollment_count":30486,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT05893420","title":"A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30000,"lead_sponsor_name":"AgileMD, Inc.","has_results":false},{"nct_id":"NCT01177111","title":"Impact of Sunflower Seed Oil Massage on Neonatal Mortality and Morbidity in Nepal","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":29260,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT06653374","title":"Perinatal Conditions Influencing Morbidity, Mortality, and Medical Care in Newborns","phase":"","overall_status":"COMPLETED","enrollment_count":26000,"lead_sponsor_name":"HOSPITAL GINECO OBSTETRICO ISIDRO AYORA","has_results":false},{"nct_id":"NCT06117605","title":"Sepsis Electronic Prompting for Timely Intervention and Care for Emergency Department Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":25668,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT05261607","title":"Analysis of the Evolution of Mortality in an Intensive Care Unit","phase":"","overall_status":"RECRUITING","enrollment_count":25000,"lead_sponsor_name":"Hospital Universitario Getafe","has_results":false},{"nct_id":"NCT05349383","title":"Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related Toxicities","phase":"","overall_status":"COMPLETED","enrollment_count":24618,"lead_sponsor_name":"Central South University","has_results":false},{"nct_id":"NCT06684340","title":"Risk Factors Identification of Sepsis and Septic Shock After Major Abdominal Surgery Based on Artificial Intelligence","phase":"","overall_status":"COMPLETED","enrollment_count":22646,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT02389036","title":"Selective Decontamination of the Digestive Tract in Intensive Care Unit Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":20010,"lead_sponsor_name":"The George Institute","has_results":false},{"nct_id":"NCT05127070","title":"Evaluating the NeoTree in Malawi and Zimbabwe","phase":"","overall_status":"UNKNOWN","enrollment_count":19000,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT04304235","title":"Paediatric Rapid Sepsis Trigger (PRST) Tool","phase":"NA","overall_status":"COMPLETED","enrollment_count":18693,"lead_sponsor_name":"University of British Columbia","has_results":true},{"nct_id":"NCT05131282","title":"Maternal Serum Markers Predicting Preeclampsia At Early Gestations","phase":"","overall_status":"COMPLETED","enrollment_count":18000,"lead_sponsor_name":"HBI Solutions Inc.","has_results":false},{"nct_id":"NCT03831490","title":"Study for Improving Maternal, Pregnancy and Child Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":13000,"lead_sponsor_name":"Uppsala University","has_results":false},{"nct_id":"NCT05311046","title":"Biomarker-enhanced Artificial Intelligence Based Pediatric Sepsis Screening Tool","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":12961,"lead_sponsor_name":"Computer Technology Associates, Inc.","has_results":false},{"nct_id":"NCT06265714","title":"The IndONEsia ICCU Registry: a Multicenter Cohort of Intensive Cardiovascular Care Units Patients in Indonesia","phase":"","overall_status":"COMPLETED","enrollment_count":12950,"lead_sponsor_name":"Indonesia University","has_results":false},{"nct_id":"NCT06117618","title":"Sepsis Electronic Prompting for Timely Intervention and Care for Inpatients","phase":"NA","overall_status":"COMPLETED","enrollment_count":12284,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT03199547","title":"Pre-delivery Administration of Azithromycin to Prevent Neonatal Sepsis & Death","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":11985,"lead_sponsor_name":"London School of Hygiene and Tropical Medicine","has_results":false},{"nct_id":"NCT03665623","title":"Prediction of Preeclampsia by Comprehensive Markers.","phase":"","overall_status":"COMPLETED","enrollment_count":11741,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT05730452","title":"Smart Discharges to Improve Post-discharge Health Outcomes in Children","phase":"NA","overall_status":"UNKNOWN","enrollment_count":11700,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT04055727","title":"Sepsis at Södersjukhuset-Adherence to Treatment Guidelines","phase":"","overall_status":"UNKNOWN","enrollment_count":11000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT06468202","title":"Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":10742,"lead_sponsor_name":"Ohio State University","has_results":false},{"nct_id":"NCT06541600","title":"Risk Factors for Adverse Outcomes in Sepsis","phase":"","overall_status":"COMPLETED","enrollment_count":10313,"lead_sponsor_name":"Qin Zhang","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}